OGT to host Company Showcase at BioTrinity 2012
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, will be discussing its biomarker discovery offering at the European Biopartnering and Investment Conference, BioTrinity, from 24th-26th April in Newbury, UK. The conference will include a Company Showcase from OGT’s CEO, Dr Mike Evans, which takes place at 4.20 pm on Wednesday 25th April. The talk will provide an overview of OGT’s corporate strategy, which has delivered significant and sustained revenue growth, with particular focus on the company’s Diagnostic Biomarkers business unit.
OGT Diagnostic Biomarkers utilises proprietary next generation technologies to identify informative biomarkers for early-stage detection of cancer and autoimmune disease. Through a combination of the implementation of a unique Biomarker Accelerator Strategy and in-house discovery, OGT is building a rich patent-protected portfolio of promising biomarkers for a number of diseases where there are clear clinical needs and markets for improved diagnostic tests. Details of this strategy and OGT’s additional biomarker discovery and validation services will be given in the presentation.
In a recent example of OGT’s Biomarker Accelerator Strategy, OGT entered into an exclusive licensing deal with Inven2, the technology transfer office at Oslo University Hospital and the University of Oslo. Using 12 highly promising colorectal cancer tissue biomarkers developed at Oslo University Hospital, OGT now has an exclusive licence to commercialise any resulting test developed with the biomarkers.
As a well-established private molecular diagnostics and clinical solutions company actively operating in 30 countries worldwide, OGT has a strong position in the large and rapidly growing molecular medicine market. To find out more about OGT and its full range of products and services, visit www.ogt.co.uk.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: contact@ogt.co.uk ; W: www.ogt.co.uk ; Twitter: @OxfordGeneTech
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Find out more
For more information about any OGT product or service, please contact us.